Clinical Trial Update: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) [Phase 1, Phase 2]

View source ↗

Summary

This Phase I/II clinical trial is evaluating Axatilimab, a CSF1R monoclonal antibody, in combination with ruxolitinib for myelofibrosis and chronic myelomonocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myelomonocytic Leukemia

Drugs mentioned

• Axatilimab (axatilimab)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1, Phase 2 | Status: RECRUITING